| 78.08 2.19 (2.89%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 93.17 | 1-year : | 98.55 |
| Resists | First : | 79.77 | Second : | 84.37 |
| Pivot price | 76.41  |
|||
| Supports | First : | 72.33 | Second : | 60.17 |
| MAs | MA(5) : | 76.32 |
MA(20) : | 77.52 |
| MA(100) : | 68.13 |
MA(250) : | 69.49 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 47.4 |
D(3) : | 40.1 |
| RSI | RSI(14): 56.3 |
|||
| 52-week | High : | 108.91 | Low : | 47.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ LNTH ] has closed below upper band by 28.9%. Bollinger Bands are 12% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 78.15 - 78.53 | 78.53 - 78.86 |
| Low: | 74.41 - 74.84 | 74.84 - 75.21 |
| Close: | 77.42 - 78.1 | 78.1 - 78.69 |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Tue, 07 Apr 2026
Lantheus Holdings: Tensions From The PDUFA Extension (NASDAQ:LNTH) - Seeking Alpha
Tue, 31 Mar 2026
Jefferies Lifts PT on Lantheus Holdings (LNTH) to $110 From $105 – Here’s Why - Yahoo Finance
Sun, 29 Mar 2026
Assenagon Asset Management S.A. Trims Position in Lantheus Holdings, Inc. $LNTH - MarketBeat
Fri, 27 Mar 2026
Vanguard disaggregates holdings; Vanguard subsidiaries to report LNTH positions (LNTH) - Stock Titan
Mon, 23 Mar 2026
CWA Asset Management Group LLC Makes New $1.67 Million Investment in Lantheus Holdings, Inc. $LNTH - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 65 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 109.3 (%) |
| Shares Short | 5,520 (K) |
| Shares Short P.Month | 4,860 (K) |
| EPS | 3.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.87 |
| Profit Margin | 15.1 % |
| Operating Margin | 19 % |
| Return on Assets (ttm) | 9.2 % |
| Return on Equity (ttm) | 21.4 % |
| Qtrly Rev. Growth | 4 % |
| Gross Profit (p.s.) | 14.46 |
| Sales Per Share | 23.65 |
| EBITDA (p.s.) | 5.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 390 (M) |
| Levered Free Cash Flow | 266 (M) |
| PE Ratio | 22.89 |
| PEG Ratio | 0 |
| Price to Book value | 4.62 |
| Price to Sales | 3.3 |
| Price to Cash Flow | 13.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|